Add to ORKGImmunotherapy with monoclonal antibody (mAb)-vehicled toxins may be a novel treatment option for the management of androgen-independent Prostate Cancer. To investigate the therapeutic potential of anti-prostate specific membrane antigen (PSMA) mAb-ricin A-chain Immunotoxins (ITS) in monolayer and 3D cell cultures of prostate carcinoma cell lines (LNCaP), (J591, PEQ226.5, PM2PO79.1)
Abstract Background Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the...
Background Although cancer of the prostate is one of the most commonly diagnosed cancers in men, no ...
AIM: Although prostate cancer is one of the most commonly diagnosed malignancies in men, there is no...
BACKGROUND: There is presently no effective therapy for relapsing, metastatic, androgen-independent ...
Unconjugated, toxin-conjugated or radiolabeled antibodies (Ab) recognizing tumor-associated antigens...
Background Prostate carcinoma is the second leading cause of cancer related death in men in western...
Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to ...
Background and aims Present antitumoral therapies against solid neoplasms are often not sufficient ...
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cance...
Abstract Prostate cancer cells are characterized by a remarkably low proliferative rate and the prod...
Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-re...
Surprisingly perhaps for a tumor where there is such clear proof of a primary hormonal basis to its ...
Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, is highly expressed by virt...
BACKGROUND: Despite the need for new prostate-specific diagnostic and therapeutic targets, very few ...
Copyright © 2013 Foroogh Nejatollahi et al. This is an open access article distributed under the Cre...
Abstract Background Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the...
Background Although cancer of the prostate is one of the most commonly diagnosed cancers in men, no ...
AIM: Although prostate cancer is one of the most commonly diagnosed malignancies in men, there is no...
BACKGROUND: There is presently no effective therapy for relapsing, metastatic, androgen-independent ...
Unconjugated, toxin-conjugated or radiolabeled antibodies (Ab) recognizing tumor-associated antigens...
Background Prostate carcinoma is the second leading cause of cancer related death in men in western...
Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to ...
Background and aims Present antitumoral therapies against solid neoplasms are often not sufficient ...
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most prostate cance...
Abstract Prostate cancer cells are characterized by a remarkably low proliferative rate and the prod...
Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-re...
Surprisingly perhaps for a tumor where there is such clear proof of a primary hormonal basis to its ...
Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, is highly expressed by virt...
BACKGROUND: Despite the need for new prostate-specific diagnostic and therapeutic targets, very few ...
Copyright © 2013 Foroogh Nejatollahi et al. This is an open access article distributed under the Cre...
Abstract Background Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the...
Background Although cancer of the prostate is one of the most commonly diagnosed cancers in men, no ...
AIM: Although prostate cancer is one of the most commonly diagnosed malignancies in men, there is no...